The global clinical immunodiagnostics market was valued at US$ 4.8 Billion in 2022 and is expected to reach US$ 8.4 Billion by 2033. The immunoassay kits & reagents segment with a market share of more than 67.0% has topped the global market within the product category and is expected to grow at a CAGR of close to 5.4% over the forecast period (2023 to 2033).
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Clinical Immunodiagnostics Market Value 2022 | US$ 4.8 Billion |
| Market Value 2023 | US$ 5.0 Billion |
| Market Value 2033 | US$ 8.4 Billion |
| CAGR 2023 to 2033 | 5.4% |
| Market Share of Top 5 Countries (2022) | 58.0% |
Clinical immunodiagnostics refers to the diagnostic tests and technologies that utilize immunodiagnostic techniques to detect and measure specific antibodies, antigens, or immune markers in patient samples. Immunodiagnostics involves the interaction between antigens and antibodies, forming an immune complex that is then detected and quantified to provide diagnostic information.
Clinical immunodiagnostics plays a crucial role in diagnosing various diseases and conditions, monitoring treatment efficacy, and assessing immune system function. These tests are commonly used in clinical laboratories, hospitals, and research institutions to identify and measure immune markers associated with infectious diseases, autoimmune disorders, allergies, cancer, and other medical conditions.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for clinical immunodiagnostics was around 3.7% of the overall US$ 128.2 Billion of the global in vitro diagnostics market in 2022.
The market has experienced significant growth over the years. The increasing prevalence of infectious diseases, autoimmune disorders, and cancer, coupled with advancements in immunodiagnostic technologies, has contributed to the expansion of the market.
The introduction of novel assays improved the sensitivity and specificity of tests, and the adoption of automated platforms has played a key role in the historic growth of the clinical immunodiagnostics market. The global burden of infectious diseases, chronic diseases, and conditions related to the immune system is expected to rise continuously in the coming years.
This will drive the demand for accurate and reliable diagnostic tests, including clinical immunodiagnostics. Also, the need for early disease detection, personalized medicine, and effective monitoring of treatment outcomes will fuel market growth.
Ongoing advancements in immunodiagnostic technologies, such as multiplex assays, high-sensitivity detection methods, and point-of-care testing, are expected to enhance the performance and accessibility of clinical immunodiagnostics. These technological advancements will enable rapid and accurate diagnosis, resulting in increased adoption and market growth.
Owed to the above factors, the global market is projected to grow at a CAGR of 5.4% in the forecasted period.
Clinical Immunodiagnostics are essential in personalized medicine because it helps in facilitating the diagnosis and monitoring of diseases at an individual level. As the demand for personalized treatment options continues to rise, clinical immunodiagnostics product manufacturers have an opportunity to develop innovative assays that enable targeted therapies and precision medicine.
The integration of clinical immunodiagnostics with therapeutics, particularly in oncology, presents opportunities for manufacturers. As targeted therapies become more prevalent, the demand for companion diagnostics is likely to grow. Developing tests that identify patients who will respond positively to specific treatments can enhance the effectiveness of therapies and reduce healthcare costs. Manufacturers can collaborate with pharmaceutical companies to develop companion diagnostic assays that enhance treatment selection and personalized patient care. This would present numerous opportunities for the growth of this market.
Principal Consultant
Clinical immunodiagnostics can involve high costs, including the development and production of assays, instruments, and reagents. The high costs associated with immunodiagnostic tests can limit their accessibility and affordability, particularly in resource-constrained settings or regions with limited healthcare budgets. Cost considerations can impact the demand for clinical immunodiagnostics.
Apart from this, clinical immunodiagnostics faces competition from alternative diagnostic technologies, such as molecular diagnostics, imaging techniques, and other non-immunological assays. These alternative technologies may offer advantages in terms of sensitivity, specificity, multiplexing capabilities, or cost-effectiveness in certain applications. The availability of alternative diagnostic options can limit the demand for clinical immunodiagnostics.
The USA occupies 91.1% of the North America market in 2022. Reimbursement policies play an important role in the adoption of medical technologies. In the USA, favorable reimbursement policies for clinical immunodiagnostics testing have supported market growth. Reimbursement coverage by government programs like Medicare and private insurance companies has incentivized healthcare providers to offer clinical immunodiagnostic-based diagnostics.
Germany’s expenditure in clinical immunodiagnostics in 2022 was US$ 310.6 Million. Personalized medicine, which involves tailoring medical treatment to individual patients based on their genetic profile, is gaining prominence in this region. Germany, known for its strong healthcare and research infrastructure, is actively participating in personalized medicine initiatives. Clinical immunodiagnostics being essential in identifying specific biomarkers for personalized medicine drives the demand for various kits and reagents in the country.
In 2022, China held a significant share of the East Asia market and is expected to grow at a CAGR of close to 6.4% over the forecast period. Chinese clinical immunodiagnostics manufacturers are increasingly collaborating with international companies, leveraging expertise, technologies, and market access. These collaborations help in technology transfer, product development, and expanding the market reach of clinical immunodiagnostics in China. Also, partnerships with healthcare providers and research institutions contribute to the growth of the clinical immunodiagnostics market in China.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By product, immunoassay kits & reagents held 67.8% market share in the world in 2022 and are expected to expand rapidly with a CAGR of 5.4% from 2023 to 2033. Immunoassay kits and reagents have a broad range of applications in clinical immunodiagnostics, covering various disease areas, including infectious diseases, autoimmune disorders, oncology, cardiovascular diseases, and endocrinology. Their versatility and adaptability to different analytes make them essential tools for diagnosing and monitoring a diverse set of medical conditions.
The market value of serum sample type was US$ 1.7 Billion, representing a sizable 35.4% market share in 2022. Serum samples are readily available and routinely used in clinical practice. Healthcare facilities and laboratories can easily collect serum samples from patients for diagnostic testing, making them a convenient and accessible source of biomaterial for immunodiagnostics.
By application, infectious disease accounted for a prominent share of the global market, with a revenue share of 20.7% in 2022. Infectious diseases are widespread and continue to pose a significant global health burden. The high prevalence of infectious diseases, such as influenza, HIV/AIDS, hepatitis, tuberculosis, and various respiratory infections, drives the demand for diagnostic tests based on immunodiagnostics.
With a 26.1% value share in 2022 and a strong CAGR of 6.4% over the projected period, the hospital has a sizable position in this market. Hospitals cater to a large number of patients with diverse medical conditions. As a result, they have a substantial demand for diagnostic testing, including clinical immunodiagnostics. Hospitals frequently utilize immunodiagnostic tests to aid in the diagnosis and inspection of various diseases.
Collaborations with medical professionals, academic institutions, and IT companies can promote creativity and speed up clinical immunodiagnostics. Also, collaboration in research, development, and commercialization can result in new applications and a larger market. The market for clinical immunodiagnostics is dominated by multiple sizable businesses. The important advances of the major companies in this market are illustrated by the following examples:
Similarly, recent developments related to the companies, manufacturing the clinical immunodiagnostics products have been tracked by the team at Future Market Insights, which are available in the full report.
| Report Attributes | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value, Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC Countries, Türkiye, South Africa and Northern Africa |
| Key Market Segments Covered | Product, Sample Type, Application, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The clinical immunodiagnostics market size is valued at US$ 5.0 billion in 2023.
The United States occupied 91.1% of the North American clinical immunodiagnostics market share in 2022.
China’s clinical immunodiagnostics market in East Asia rose at a 6.4% CAGR in 2022.
The immunoassay kits & reagents segment will thrive at a 5.4% CAGR from 2023 to 2033.
The infectious disease segment garnered 20.7% of the clinical immunodiagnostics market’s revenue share in 2022.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value-Added Insights 4.1. Product Adoption / Usage Analysis 4.2. Product USPs / features 4.3. Recent Product Approvals and Launches 4.4. Regulatory Scenario, By Country 4.5. PESTLE Analysis 4.6. Porter’s Analysis 4.7. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Industry Market Outlook 5.1.2. Life Science Market Outlook 5.1.3. In Vitro Diagnostics Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Growing Prevalence of Immunological Disorders 5.2.2. Increasing Prevalence of Infectious Diseases 5.2.3. Increased Focus on Personalized Medicine 5.2.4. Growing Investment in Healthcare Expenditures 5.2.5. Technological Advancements 5.2.6. Increasing Number of Immunoassay Kit Manufacturers 5.2.7. Cost of Products 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand in Volume (Units) Analysis 2017 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Volume (Units) Analysis, 2017 to 2022 6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 7. Global Market - Pricing Analysis 7.1. Regional Pricing Analysis, By Product 7.2. Global Average Pricing Analysis Benchmark 7.3. Pricing Assumptions 8. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 8.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 8.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 8.3. Revenue Opportunity Scenario 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Product, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Product, 2023 to 2033 9.3.1. Immunoassay Kits & Reagents 9.3.2. Analyzers & Instrument 9.3.3. Software 9.4. Market Attractiveness Analysis, By Product 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Sample Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis, By Sample Type, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Sample Type, 2023 to 2033 10.3.1. Serum 10.3.2. Plasma 10.3.3. Urine 10.3.4. Cerebrospinal Fluid 10.3.5. Others 10.4. Market Attractiveness Analysis, By Sample Type 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis, By Application, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Application, 2023 to 2033 11.3.1. Infectious Disease 11.3.2. Cardiac Disease 11.3.3. Diabetes 11.3.4. Autoimmune Disorders 11.3.5. Inflammatory Maker 11.3.6. Kidney & Liver Disease 11.3.7. Oncology 11.3.8. Others 11.4. Market Attractiveness Analysis, By Application 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis, By End User, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2023 to 2033 12.3.1. Hospital 12.3.2. Specialty Clinics 12.3.3. Academic and Research Institute 12.3.4. Diagnostics Laboratories 12.3.5. Reference Laboratories 12.3.6. Cancer Research Institutes 12.3.7. Veterinary Hospitals 12.3.8. Blood Banks 12.4. Market Attractiveness Analysis, By End User 13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 13.1. Introduction 13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Region, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Region, 2023 to 2033 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. East Asia 13.3.5. South Asia 13.3.6. Oceania 13.3.7. Middle East & Africa 13.4. Market Attractiveness Analysis, By Region 14. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) and Volume (Units)Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. USA. 14.3.1.2. Canada 14.3.2. By Product 14.3.3. By Sample Type 14.3.4. By Application 14.3.5. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product 14.4.3. By Sample Type 14.4.4. By Application 14.4.5. By End User 14.5. Drivers and Restraints - Impact Analysis 14.6. Country Level Analysis & Forecast 14.6.1. USA. Market Analysis 14.6.1.1. Introduction 14.6.1.2. Market Analysis and Forecast by Market Taxonomy 14.6.1.2.1. By Product 14.6.1.2.2. By Sample Type 14.6.1.2.3. By Application 14.6.1.2.4. By End User 14.6.2. Canada Market Analysis 14.6.2.1. Introduction 14.6.2.2. Market Analysis and Forecast by Market Taxonomy 14.6.2.2.1. By Product 14.6.2.2.2. By Sample Type 14.6.2.2.3. By Application 14.6.2.2.4. By End User 15. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Volume (Units) and Trend Analysis, By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Mexico 15.3.1.2. Brazil 15.3.1.3. Argentina 15.3.1.4. Rest of Latin America 15.3.2. By Product 15.3.3. By Sample Type 15.3.4. By Application 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product 15.4.3. By Sample Type 15.4.4. By Application 15.4.5. By End User 15.5. Drivers and Restraints - Impact Analysis 15.6. Country Level Analysis & Forecast 15.6.1. Mexico Market Analysis 15.6.1.1. Introduction 15.6.1.2. Market Analysis and Forecast by Market Taxonomy 15.6.1.2.1. By Product 15.6.1.2.2. By Sample Type 15.6.1.2.3. By Application 15.6.1.2.4. By End User 15.6.2. Brazil Market Analysis 15.6.2.1. Introduction 15.6.2.2. Market Analysis and Forecast by Market Taxonomy 15.6.2.2.1. By Product 15.6.2.2.2. By Sample Type 15.6.2.2.3. By Application 15.6.2.2.4. By End User 15.6.3. Argentina Market Analysis 15.6.3.1. Introduction 15.6.3.2. Market Analysis and Forecast by Market Taxonomy 15.6.3.2.1. By Product 15.6.3.2.2. By Sample Type 15.6.3.2.3. By Application 15.6.3.2.4. By End User 16. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. United Kingdom. 16.3.1.2. Germany 16.3.1.3. Italy 16.3.1.4. France 16.3.1.5. Spain 16.3.1.6. Russia 16.3.1.7. BENELUX 16.3.1.8. Rest of Europe 16.3.2. By Product 16.3.3. By Sample Type 16.3.4. By Application 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product 16.4.3. By Sample Type 16.4.4. By Application 16.4.5. By End User 16.5. Drivers and Restraints - Impact Analysis 16.6. Country Level Analysis & Forecast 16.6.1. United Kingdom. Market Analysis 16.6.1.1. Introduction 16.6.1.2. Market Analysis and Forecast by Market Taxonomy 16.6.1.2.1. By Product 16.6.1.2.2. By Sample Type 16.6.1.2.3. By Application 16.6.1.2.4. By End User 16.6.2. Germany Market Analysis 16.6.2.1. Introduction 16.6.2.2. Market Analysis and Forecast by Market Taxonomy 16.6.2.2.1. By Product 16.6.2.2.2. By Sample Type 16.6.2.2.3. By Application 16.6.2.2.4. By End User 16.6.3. Italy Market Analysis 16.6.3.1. Introduction 16.6.3.2. Market Analysis and Forecast by Market Taxonomy 16.6.3.2.1. By Product 16.6.3.2.2. By Sample Type 16.6.3.2.3. By Application 16.6.3.2.4. By End User 16.6.4. France Market Analysis 16.6.4.1. Introduction 16.6.4.2. Market Analysis and Forecast by Market Taxonomy 16.6.4.2.1. By Product 16.6.4.2.2. By Sample Type 16.6.4.2.3. By Application 16.6.4.2.4. By End User 16.6.5. Spain Market Analysis 16.6.5.1. Introduction 16.6.5.2. Market Analysis and Forecast by Market Taxonomy 16.6.5.2.1. By Product 16.6.5.2.2. By Sample Type 16.6.5.2.3. By Application 16.6.5.2.4. By End User 16.6.6. Russia Market Analysis 16.6.6.1. Introduction 16.6.6.2. Market Analysis and Forecast by Market Taxonomy 16.6.6.2.1. By Product 16.6.6.2.2. By Sample Type 16.6.6.2.3. By Application 16.6.6.2.4. By End User 16.6.7. BENELUX Market Analysis 16.6.7.1. Introduction 16.6.7.2. Market Analysis and Forecast by Market Taxonomy 16.6.7.2.1. By Product 16.6.7.2.2. By Sample Type 16.6.7.2.3. By Application 16.6.7.2.4. By End User 17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Product 17.3.3. By Sample Type 17.3.4. By Application 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product 17.4.3. By Sample Type 17.4.4. By Application 17.4.5. By End User 17.5. Drivers and Restraints - Impact Analysis 17.6. Country Level Analysis & Forecast 17.6.1. China Market Analysis 17.6.1.1. Introduction 17.6.1.2. Market Analysis and Forecast by Market Taxonomy 17.6.1.2.1. By Product 17.6.1.2.2. By Sample Type 17.6.1.2.3. By Application 17.6.1.2.4. By End User 17.6.2. Japan Market Analysis 17.6.2.1. Introduction 17.6.2.2. Market Analysis and Forecast by Market Taxonomy 17.6.2.2.1. By Product 17.6.2.2.2. By Sample Type 17.6.2.2.3. By Application 17.6.2.2.4. By End User 17.6.3. South Korea Market Analysis 17.6.3.1. Introduction 17.6.3.2. Market Analysis and Forecast by Market Taxonomy 17.6.3.2.1. By Product 17.6.3.2.2. By Sample Type 17.6.3.2.3. By Application 17.6.3.2.4. By End User 18. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. India 18.3.1.2. Indonesia 18.3.1.3. Malaysia 18.3.1.4. Thailand 18.3.1.5. Rest of South Asia 18.3.2. By Product 18.3.3. By Sample Type 18.3.4. By Application 18.3.5. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Product 18.4.3. By Sample Type 18.4.4. By Application 18.4.5. By End User 18.5. Drivers and Restraints - Impact Analysis 18.6. Country Level Analysis & Forecast 18.6.1. India Market Analysis 18.6.1.1. Introduction 18.6.1.2. Market Analysis and Forecast by Market Taxonomy 18.6.1.2.1. By Product 18.6.1.2.2. By Sample Type 18.6.1.2.3. By Application 18.6.1.2.4. By End User 18.6.2. Indonesia Market Analysis 18.6.2.1. Introduction 18.6.2.2. Market Analysis and Forecast by Market Taxonomy 18.6.2.2.1. By Product 18.6.2.2.2. By Sample Type 18.6.2.2.3. By Application 18.6.2.2.4. By End User 18.6.3. Malaysia Market Analysis 18.6.3.1. Introduction 18.6.3.2. Market Analysis and Forecast by Market Taxonomy 18.6.3.2.1. By Product 18.6.3.2.2. By Sample Type 18.6.3.2.3. By Application 18.6.3.2.4. By End User 18.6.4. Thailand Market Analysis 18.6.4.1. Introduction 18.6.4.2. Market Analysis and Forecast by Market Taxonomy 18.6.4.2.1. By Product 18.6.4.2.2. By Sample Type 18.6.4.2.3. By Application 18.6.4.2.4. By End User 19. Oceania Market 2017 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. Australia 19.3.1.2. New Zealand 19.3.2. By Product 19.3.3. By Sample Type 19.3.4. By Application 19.3.5. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Product 19.4.3. By Sample Type 19.4.4. By Application 19.4.5. By End User 19.5. Drivers and Restraints - Impact Analysis 19.6. Country Level Analysis & Forecast 19.6.1. Australia Market Analysis 19.6.1.1. Introduction 19.6.1.2. Market Analysis and Forecast by Market Taxonomy 19.6.1.2.1. By Product 19.6.1.2.2. By Sample Type 19.6.1.2.3. By Application 19.6.1.2.4. By End User 19.6.2. New Zealand Market Analysis 19.6.2.1. Introduction 19.6.2.2. Market Analysis and Forecast by Market Taxonomy 19.6.2.2.1. By Product 19.6.2.2.2. By Sample Type 19.6.2.2.3. By Application 19.6.2.2.4. By End User 20. Middle East & Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022 20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. GCC Countries 20.3.1.2. Türkiye 20.3.1.3. South Africa 20.3.1.4. Northern Africa 20.3.1.5. Rest of Middle East & Africa 20.3.2. By Product 20.3.3. By Sample Type 20.3.4. By Application 20.3.5. By End User 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Product 20.4.3. By Sample Type 20.4.4. By Application 20.4.5. By End User 20.5. Drivers and Restraints - Impact Analysis 20.6. Country Level Analysis & Forecast 20.6.1. GCC Countries Market Analysis 20.6.1.1. Introduction 20.6.1.2. Market Analysis and Forecast by Market Taxonomy 20.6.1.2.1. By Product 20.6.1.2.2. By Sample Type 20.6.1.2.3. By Application 20.6.1.2.4. By End User 20.6.2. Türkiye Market Analysis 20.6.2.1. Introduction 20.6.2.2. Market Analysis and Forecast by Market Taxonomy 20.6.2.2.1. By Product 20.6.2.2.2. By Sample Type 20.6.2.2.3. By Application 20.6.2.2.4. By End User 20.6.3. South Africa Market Analysis 20.6.3.1. Introduction 20.6.3.2. Market Analysis and Forecast by Market Taxonomy 20.6.3.2.1. By Product 20.6.3.2.2. By Sample Type 20.6.3.2.3. By Application 20.6.3.2.4. By End User 20.6.4. Northern Africa Market Analysis 20.6.4.1. Introduction 20.6.4.2. Market Analysis and Forecast by Market Taxonomy 20.6.4.2.1. By Product 20.6.4.2.2. By Sample Type 20.6.4.2.3. By Application 20.6.4.2.4. By End User 21. Market Structure Analysis 21.1. Market Analysis, By Tier of Companies 21.2. Market Share Analysis of Top Players 21.3. Market Presence Analysis 21.3.1. By Regional Footprint of Players 21.3.2. Product Footprint of Players 21.3.3. Channel Footprint of Players 22. Competition Analysis 22.1. Competition Dashboard 22.2. Branding and Promotional Strategies by Key Players 22.3. Key Development Analysis 22.4. Competition Deep Dive 22.4.1. Surmodics, Inc. 22.4.1.1. Overview 22.4.1.2. Product Portfolio 22.4.1.3. Key Financials 22.4.1.4. Sales Footprint 22.4.1.5. Key Developments 22.4.1.6. Strategy Overview 22.4.1.6.1. Marketing Strategy 22.4.1.6.2. Product Strategy 22.4.1.6.3. Channel Strategy 22.4.2. MESO SCALE DIAGNOSTICS, LLC. 22.4.2.1. Overview 22.4.2.2. Product Portfolio 22.4.2.3. Key Financials 22.4.2.4. Sales Footprint 22.4.2.5. Key Developments 22.4.2.6. Strategy Overview 22.4.2.6.1. Marketing Strategy 22.4.2.6.2. Product Strategy 22.4.2.6.3. Channel Strategy 22.4.3. Abbott 22.4.3.1. Overview 22.4.3.2. Product Portfolio 22.4.3.3. Key Financials 22.4.3.4. Sales Footprint 22.4.3.5. Key Developments 22.4.3.6. Strategy Overview 22.4.3.6.1. Marketing Strategy 22.4.3.6.2. Product Strategy 22.4.3.6.3. Channel Strategy 22.4.4. Siemens Healthineers 22.4.4.1. Overview 22.4.4.2. Product Portfolio 22.4.4.3. Key Financials 22.4.4.4. Sales Footprint 22.4.4.5. Key Developments 22.4.4.6. Strategy Overview 22.4.4.6.1. Marketing Strategy 22.4.4.6.2. Product Strategy 22.4.4.6.3. Channel Strategy 22.4.5. PerkinElmer Inc. 22.4.5.1. Overview 22.4.5.2. Product Portfolio 22.4.5.3. Key Financials 22.4.5.4. Sales Footprint 22.4.5.5. Key Developments 22.4.5.6. Strategy Overview 22.4.5.6.1. Marketing Strategy 22.4.5.6.2. Product Strategy 22.4.5.6.3. Channel Strategy 22.4.6. Becton, Dickinson and Company 22.4.6.1. Overview 22.4.6.2. Product Portfolio 22.4.6.3. Key Financials 22.4.6.4. Sales Footprint 22.4.6.5. Key Developments 22.4.6.6. Strategy Overview 22.4.6.6.1. Marketing Strategy 22.4.6.6.2. Product Strategy 22.4.6.6.3. Channel Strategy 22.4.7. Thermo Fisher Scientific Inc. 22.4.7.1. Overview 22.4.7.2. Product Portfolio 22.4.7.3. Key Financials 22.4.7.4. Sales Footprint 22.4.7.5. Key Developments 22.4.7.6. Strategy Overview 22.4.7.6.1. Marketing Strategy 22.4.7.6.2. Product Strategy 22.4.7.6.3. Channel Strategy 22.4.8. Zoetis Inc. 22.4.8.1. Overview 22.4.8.2. Product Portfolio 22.4.8.3. Key Financials 22.4.8.4. Sales Footprint 22.4.8.5. Key Developments 22.4.8.6. Strategy Overview 22.4.8.6.1. Marketing Strategy 22.4.8.6.2. Product Strategy 22.4.8.6.3. Channel Strategy 22.4.9. Promega Corporation 22.4.9.1. Overview 22.4.9.2. Product Portfolio 22.4.9.3. Key Financials 22.4.9.4. Sales Footprint 22.4.9.5. Key Developments 22.4.9.6. Strategy Overview 22.4.9.6.1. Marketing Strategy 22.4.9.6.2. Product Strategy 22.4.9.6.3. Channel Strategy 22.4.10. F. Hoffmann-La Roche 22.4.10.1. Overview 22.4.10.2. Product Portfolio 22.4.10.3. Key Financials 22.4.10.4. Sales Footprint 22.4.10.5. Key Developments 22.4.10.6. Strategy Overview 22.4.10.6.1. Marketing Strategy 22.4.10.6.2. Product Strategy 22.4.10.6.3. Channel Strategy 22.4.11. BIOMÉRIEUX SA 22.4.11.1. Overview 22.4.11.2. Product Portfolio 22.4.11.3. Key Financials 22.4.11.4. Sales Footprint 22.4.11.5. Key Developments 22.4.11.6. Strategy Overview 22.4.11.6.1. Marketing Strategy 22.4.11.6.2. Product Strategy 22.4.11.6.3. Channel Strategy 22.4.12. Elabscience Biotechnology Inc. 22.4.12.1. Overview 22.4.12.2. Product Portfolio 22.4.12.3. Key Financials 22.4.12.4. Sales Footprint 22.4.12.5. Key Developments 22.4.12.6. Strategy Overview 22.4.12.6.1. Marketing Strategy 22.4.12.6.2. Product Strategy 22.4.12.6.3. Channel Strategy 22.4.13. Innovative Research, Inc. 22.4.13.1. Overview 22.4.13.2. Product Portfolio 22.4.13.3. Key Financials 22.4.13.4. Sales Footprint 22.4.13.5. Key Developments 22.4.13.6. Strategy Overview 22.4.13.6.1. Marketing Strategy 22.4.13.6.2. Product Strategy 22.4.13.6.3. Channel Strategy 22.4.14. QIAGEN N.V. 22.4.14.1. Overview 22.4.14.2. Product Portfolio 22.4.14.3. Key Financials 22.4.14.4. Sales Footprint 22.4.14.5. Key Developments 22.4.14.6. Strategy Overview 22.4.14.6.1. Marketing Strategy 22.4.14.6.2. Product Strategy 22.4.14.6.3. Channel Strategy 22.4.15. Merck KGaA 22.4.15.1. Overview 22.4.15.2. Product Portfolio 22.4.15.3. Key Financials 22.4.15.4. Sales Footprint 22.4.15.5. Key Developments 22.4.15.6. Strategy Overview 22.4.15.6.1. Marketing Strategy 22.4.15.6.2. Product Strategy 22.4.15.6.3. Channel Strategy 22.4.16. Bio-Rad Laboratories, Inc. 22.4.16.1. Overview 22.4.16.2. Product Portfolio 22.4.16.3. Key Financials 22.4.16.4. Sales Footprint 22.4.16.5. Key Developments 22.4.16.6. Strategy Overview 22.4.16.6.1. Marketing Strategy 22.4.16.6.2. Product Strategy 22.4.16.6.3. Channel Strategy 22.4.17. Creative Diagnostics 22.4.17.1. Overview 22.4.17.2. Product Portfolio 22.4.17.3. Key Financials 22.4.17.4. Sales Footprint 22.4.17.5. Key Developments 22.4.17.6. Strategy Overview 22.4.17.6.1. Marketing Strategy 22.4.17.6.2. Product Strategy 22.4.17.6.3. Channel Strategy 22.4.18. Cell Signaling Technology (CST) 22.4.18.1. Overview 22.4.18.2. Product Portfolio 22.4.18.3. Key Financials 22.4.18.4. Sales Footprint 22.4.18.5. Key Developments 22.4.18.6. Strategy Overview 22.4.18.6.1. Marketing Strategy 22.4.18.6.2. Product Strategy 22.4.18.6.3. Channel Strategy 22.4.19. NEW HORIZONS DIAGNOSTIC CORPORATION 22.4.19.1. Overview 22.4.19.2. Product Portfolio 22.4.19.3. Key Financials 22.4.19.4. Sales Footprint 22.4.19.5. Key Developments 22.4.19.6. Strategy Overview 22.4.19.6.1. Marketing Strategy 22.4.19.6.2. Product Strategy 22.4.19.6.3. Channel Strategy 22.4.20. DiaSorin S.p.A. 22.4.20.1. Overview 22.4.20.2. Product Portfolio 22.4.20.3. Key Financials 22.4.20.4. Sales Footprint 22.4.20.5. Key Developments 22.4.20.6. Strategy Overview 22.4.20.6.1. Marketing Strategy 22.4.20.6.2. Product Strategy 22.4.20.6.3. Channel Strategy 22.4.21. H.U. Group Holdings Inc 22.4.21.1. Overview 22.4.21.2. Product Portfolio 22.4.21.3. Key Financials 22.4.21.4. Sales Footprint 22.4.21.5. Key Developments 22.4.21.6. Strategy Overview 22.4.21.6.1. Marketing Strategy 22.4.21.6.2. Product Strategy 22.4.21.6.3. Channel Strategy 22.4.22. IDEXX Laboratories Inc. 22.4.22.1. Overview 22.4.22.2. Product Portfolio 22.4.22.3. Key Financials 22.4.22.4. Sales Footprint 22.4.22.5. Key Developments 22.4.22.6. Strategy Overview 22.4.22.6.1. Marketing Strategy 22.4.22.6.2. Product Strategy 22.4.22.6.3. Channel Strategy 22.4.23. Randox Laboratories Ltd. 22.4.23.1. Overview 22.4.23.2. Product Portfolio 22.4.23.3. Key Financials 22.4.23.4. Sales Footprint 22.4.23.5. Key Developments 22.4.23.6. Strategy Overview 22.4.23.6.1. Marketing Strategy 22.4.23.6.2. Product Strategy 22.4.23.6.3. Channel Strategy 22.4.24. Biopanda Reagents Ltd. 22.4.24.1. Overview 22.4.24.2. Product Portfolio 22.4.24.3. Key Financials 22.4.24.4. Sales Footprint 22.4.24.5. Key Developments 22.4.24.6. Strategy Overview 22.4.24.6.1. Marketing Strategy 22.4.24.6.2. Product Strategy 22.4.24.6.3. Channel Strategy 22.4.25. Shenzhen Bioeasy Biotechnology Co., Ltd. 22.4.25.1. Overview 22.4.25.2. Product Portfolio 22.4.25.3. Key Financials 22.4.25.4. Sales Footprint 22.4.25.5. Key Developments 22.4.25.6. Strategy Overview 22.4.25.6.1. Marketing Strategy 22.4.25.6.2. Product Strategy 22.4.25.6.3. Channel Strategy 22.4.26. Quidel Corporation 22.4.26.1. Overview 22.4.26.2. Product Portfolio 22.4.26.3. Key Financials 22.4.26.4. Sales Footprint 22.4.26.5. Key Developments 22.4.26.6. Strategy Overview 22.4.26.6.1. Marketing Strategy 22.4.26.6.2. Product Strategy 22.4.26.6.3. Channel Strategy 22.4.27. Advnt Biotechnologies. 22.4.27.1. Overview 22.4.27.2. Product Portfolio 22.4.27.3. Key Financials 22.4.27.4. Sales Footprint 22.4.27.5. Key Developments 22.4.27.6. Strategy Overview 22.4.27.6.1. Marketing Strategy 22.4.27.6.2. Product Strategy 22.4.27.6.3. Channel Strategy 22.4.28. RESPONSE BIOMEDICAL. 22.4.28.1. Overview 22.4.28.2. Product Portfolio 22.4.28.3. Key Financials 22.4.28.4. Sales Footprint 22.4.28.5. Key Developments 22.4.28.6. Strategy Overview 22.4.28.6.1. Marketing Strategy 22.4.28.6.2. Product Strategy 22.4.28.6.3. Channel Strategy 22.4.29. Danaher Corporation 22.4.29.1. Overview 22.4.29.2. Product Portfolio 22.4.29.3. Key Financials 22.4.29.4. Sales Footprint 22.4.29.5. Key Developments 22.4.29.6. Strategy Overview 22.4.29.6.1. Marketing Strategy 22.4.29.6.2. Product Strategy 22.4.29.6.3. Channel Strategy 23. Assumptions and Acronyms Used 24. Research Methodology
Explore Healthcare Insights
View Reports
Clinical Immunodiagnostics Market
